How can blocking and activating the same receptor both work?

That is the open question. Leading explanations are that antagonism improves tolerability so more GLP-1 can be given, that chronic agonism desensitises the receptor into a similar state, or that central and peripheral GIP receptors differ in role.

Does this mean GIP agonism is not why tirzepatide works better?

It means the inference is less secure than it appears. Adding GIPR engagement clearly helps; the direction of that engagement is unresolved.

Is either approach proven superior?

No. Tirzepatide has approval and pivotal data; the antagonist approach has preclinical and early clinical evidence. No head-to-head resolution exists.

GLP-1 & Incretin Science

The GIP Paradox: Why Agonism and Antagonism Both Produce Weight Loss

JMWritten & reviewed by Jack Muncaster · Founder, UK PeptidesLast reviewed 2026-08-234 cited sources

Tirzepatide activates the GIP receptor and produces up to 22.5% weight reduction. Maridebart cafraglutide blocks the same receptor and also produces substantial reduction. Both are paired with GLP-1 agonism, both work, and whether GIPR should be agonised or antagonised for obesity remains genuinely unresolved.

Key facts

GIPR agonist example: Tirzepatide (with GLP-1 agonism)
GIPR antagonist example: Maridebart cafraglutide (MariTide)
Shared component: Both include GLP-1 receptor agonism
Status of the question: Unresolved
Leading hypothesis: Antagonism may improve tolerability
Key review: Annu Rev Nutr 2026 (PMID 42166683)

The contradiction, stated plainly

Tirzepatide is a dual agonist: it activates both the GIP and GLP-1 receptors, and it produces greater weight reduction than GLP-1 agonism alone. Maridebart cafraglutide is a bispecific molecule that does the opposite at GIPR — a monoclonal antibody that blocks the receptor, conjugated to two GLP-1 agonist peptides. It also produces pronounced dose-dependent weight reduction. Two compounds doing opposite things at the same receptor, both apparently working.

Why this is not simply an error somewhere

It would be tidier if one programme rested on a misreading, but both have clinical data. Tirzepatide is an approved medicine with pivotal trials behind it. The GIPR antagonist approach was reported in Nature Metabolism in 2024 with preclinical and Phase 1 evidence of dose-dependent reduction and an acceptable tolerability profile. A 2026 review in the Annual Review of Nutrition addresses the paradox directly rather than dismissing either side.

Hypothesis one: it is about tolerability, not efficacy

The most discussed explanation is that GIPR antagonism reduces nausea. If blocking GIPR improves tolerability of a co-administered GLP-1 agonist, then more GLP-1 agonism can be delivered before adverse effects force a dose reduction. On that reading the antagonist is not producing weight loss through GIPR at all — it is removing the ceiling on how much GLP-1 signalling a person can tolerate. The weight reduction would still be GLP-1-driven.

Hypothesis two: chronic agonism becomes functional antagonism

Sustained agonism at a G-protein-coupled receptor commonly causes desensitisation and receptor internalisation. If continuous GIPR agonism downregulates the receptor, then long-term agonism and pharmacological blockade could converge on a similar functional state — reduced GIPR signalling — by different routes. This would make the paradox apparent rather than real, but it is a hypothesis rather than a demonstrated mechanism.

Hypothesis three: central and peripheral GIPR do different things

GIP receptors are expressed in adipose tissue, pancreas and brain, including regions relevant to appetite. If the receptor's role differs by tissue, a molecule reaching central receptors could produce an effect opposite to one acting principally in the periphery. Molecule size and blood-brain-barrier penetration then matter as much as whether a compound agonises or antagonises.

What emerging data suggests

Work reported through 2026 supports the notion that GIPR agonism and antagonism can each provide additive weight reduction when combined with a GLP-1 receptor agonist. A 2026 comparison in male mice examined the two approaches head to head metabolically. None of this yet resolves which is preferable in humans, and it is unusual for a field to advance two opposite pharmacologies this far without settling the question.

Why it matters for reading the field

Any confident claim that GIP agonism is the reason tirzepatide outperforms semaglutide should be read carefully. It is consistent with the data and it may well be right, but a competing programme built on the opposite premise is producing results too. The honest position is that adding GIPR engagement to GLP-1 agonism helps, and the direction of that engagement is not settled.

Quick reference

	Tirzepatide	Maridebart cafraglutide
GIPR action	Agonist	Antagonist
GLP-1R action	Agonist	Agonist
Format	Single peptide	Antibody + 2 peptides
Status	Approved	Investigational
Outcome	Weight reduction	Weight reduction

Extended research context

The GLP-1 & Incretin Science deep dive

Deep dive: the two routes to a bigger effect

Every compound trying to beat GLP-1 alone has taken one of two routes. The first adds more receptors from the same hormone family — GIP in tirzepatide, GIP and glucagon in retatrutide. The second adds a non-incretin satiety hormone, which in practice means amylin: CagriSema combines cagrilintide with semaglutide, and amycretin engages both receptors from one molecule. Both routes work, because they recruit signalling pathways that do not fully overlap. Neither has escaped the constraint that binds all of them, which is that gastrointestinal tolerability worsens as effect size grows.

Deep dive: why a percentage is not a result

The most-quoted numbers in this field are the least comparable. REDEFINE 1 reported 22.7% and 20.4% for the same compound in the same trial — the first among participants who adhered to treatment, the second across everyone randomised. TRIUMPH-1 reported 28.3% in an uncomplicated obesity population while TRIUMPH-3 reported up to 22.6% in adults with established cardiovascular disease, using the same compound. Before any two figures can be compared they have to match on estimand, population, duration, comparator and whether the number is placebo-adjusted. Most published comparisons match on none of them.

Deep dive: what happens after the trial stops

Every headline figure describes weight while treatment continues. The STEP-1 extension found that a year after semaglutide was stopped, participants had given back roughly two-thirds of what they lost, moving from 17.3% mean reduction to a net 5.6% — though average weight remained below baseline and nearly half stayed at least 5% down. Meta-analysis puts regain at around 0.8 kg per month. This is why maintenance studies such as TRIUMPH-6 matter more to the field's future than another two points of peak reduction.

Research applications

▸Comparing incretin and amylin compounds on a like-for-like basis
▸Interpreting estimands, thresholds and placebo-adjusted figures in trial reports
▸Tracking the obesity pipeline across sponsors and jurisdictions
▸Understanding receptor pharmacology behind GLP-1, GIP, glucagon and amylin
▸Distinguishing licensed medicines from investigational compounds

Handling checklist

✓Identify which estimand a quoted percentage comes from before citing it
✓Check the trial population and baseline BMI against the comparison you are making
✓Confirm the duration and whether the reduction curve had plateaued
✓Read discontinuation rates alongside efficacy figures
✓Verify every NCT identifier against ClinicalTrials.gov rather than secondary reporting

Common research-handling mistakes

Learnt from thousands of researcher orders across our UK labs.

✗ Comparing headline percentages across different trials

Fix: Population, duration, estimand and comparator all differ; the numbers are not interchangeable.

✗ Quoting the larger of two figures from the same trial

Fix: Name the estimand. Efficacy and treatment-policy answer different questions.

✗ Treating peak reduction as a durable outcome

Fix: Substantial regain follows cessation across the class; peak figures describe a maintained state.

✗ Assuming an oral route means a weaker mechanism

Fix: Route and receptor count are independent. Orforglipron is weaker because it hits one receptor, not because it is a tablet.

✗ Reading investigational compounds as available treatments

Fix: Most of this pipeline holds no authorisation anywhere; mazdutide is approved only in China.

Continue researching

Peer-reviewed guides, comparators and matched reference materials.

Frequently asked questions

How can blocking and activating the same receptor both work?: That is the open question. Leading explanations are that antagonism improves tolerability so more GLP-1 can be given, that chronic agonism desensitises the receptor into a similar state, or that central and peripheral GIP receptors differ in role.
Does this mean GIP agonism is not why tirzepatide works better?: It means the inference is less secure than it appears. Adding GIPR engagement clearly helps; the direction of that engagement is unresolved.
Is either approach proven superior?: No. Tirzepatide has approval and pivotal data; the antagonist approach has preclinical and early clinical evidence. No head-to-head resolution exists.

Primary sources & clinical trials

Peer-reviewed research and registered trials from PubMed, ClinicalTrials.gov, PubChem, FDA and NIH. All links open in a new tab and point to the primary source, so every claim can be verified at origin.

Written and reviewed by

Jack Muncaster · Founder, UK Peptides

Jack founded UK Peptides in Manchester after repeatedly receiving research compounds with missing or recycled paperwork. He is responsible for supplier selection, batch release decisions and the content published in this research library. Every article here is sourced to primary literature and every product page to a signed third-party certificate.

How we write and check this content Report a factual error in this article

More GLP-1 & Incretin Science articles

Popular across the research hub

One flagship guide from every other research category — keep exploring.

← Back to Forum